Nitric Oxide-Releasing Nanoparticles Prevent Propionibacterium Acnes-Induced Inflammation by Both Clearing the Organism and Inhibiting Microbial Stimulation of the Innate Immune Response
Overview
Authors
Affiliations
Propionibacterium acnes induction of IL-1 cytokines through the NLRP3 (NLR, nucleotide oligomerization domain-like receptor) inflammasome was recently highlighted as a dominant etiological factor for acne vulgaris. Therefore, therapeutics targeting both the stimulus and the cascade would be ideal. Nitric oxide (NO), a potent biological messenger, has documented broad-spectrum antimicrobial and immunomodulatory properties. To harness these characteristics to target acne, we used an established nanotechnology capable of generating/releasing NO over time (NO-np). P. acnes was found to be highly sensitive to all concentrations of NO-np tested, although human keratinocyte, monocyte, and embryonic zebra fish assays revealed no cytotoxicity. NO-np significantly suppressed IL-1β, tumor necrosis factor-α (TNF-α), IL-8, and IL-6 from human monocytes, and IL-8 and IL-6 from human keratinocytes, respectively. Importantly, silencing of NLRP3 expression by small interfering RNA did not limit NO-np inhibition of IL-1 β secretion from monocytes, and neither TNF-α nor IL-6 secretion, nor inhibition by NO-np was found to be dependent on this pathway. The observed mechanism by which NO-np impacts IL-1β secretion was through inhibition of caspase-1 and IL-1β gene expression. Together, these data suggest that NO-np can effectively prevent P. acnes-induced inflammation by both clearing the organism and inhibiting microbial stimulation of the innate immune response.
and Activity of a New N-Oxide Derivative for Acne Vulgaris Treatment.
Delgado I, Scarim C, Fernandes F, Barbieri K, Polesi M, Pavan A Med Chem. 2024; 21(1):32-45.
PMID: 39082171 DOI: 10.2174/0115734064306187240722070225.
Acne treatment: research progress and new perspectives.
Li Y, Hu X, Dong G, Wang X, Liu T Front Med (Lausanne). 2024; 11:1425675.
PMID: 39050538 PMC: 11266290. DOI: 10.3389/fmed.2024.1425675.
Alvi S, Pracha N, Shalaan M, Dholaniya P, Mergaye M, Sridharan D Biomedicines. 2024; 12(6).
PMID: 38927571 PMC: 11201505. DOI: 10.3390/biomedicines12061363.
Targeting Inflammation in Acne: Current Treatments and Future Prospects.
Cruz S, Vecerek N, Elbuluk N Am J Clin Dermatol. 2023; 24(5):681-694.
PMID: 37328614 PMC: 10460329. DOI: 10.1007/s40257-023-00789-1.
Effects of Tocilizumab on Inflammation and Iron Metabolism in Critically Ill Patients with COVID-19.
Szabo R, Petrisor C, Bodolea C, Dobre V, Tranca S, Clichici S Pharmaceutics. 2023; 15(2).
PMID: 36839968 PMC: 9960594. DOI: 10.3390/pharmaceutics15020646.